Elotuzumab is a humanized IgG1 monoclonal antibody which targets SLAMF7, known as CS1, a glycoprotein, intensely expressed on MM cells and normal plasma cells as well as natural killer (NK) cells. This evidence concerns the gene SLAMF7 and Miyoshi myopathy.